EGFR and non-small cell lung carcinoma: Likewise, in 89 NSCLC patients receiving either gefitinib or erlotinib as first- or second-line systemic therapy, a statistically significant positive linear correlation was found between adjusted (normalized to the proportion of neoplastic cells in each specimen) VAF of EGFR variant in tumoral tissue (aVAF) and PFS (r = 0.319; p = 0.002) [53].